CD274 and neoplasm: To date, three biomarkers have been approved by the United States Food and Drug Administration (FDA) [25], namely PD-L1 expression on tumor cells, microsatellite Instability/defective mismatch repair (MSI/dMMR) [26] and tumor mutational burden (TMB) [27].